Company Overview

Xeris Biopharma Holdings, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for endocrine, neurology, and gastrointestinal diseases. The company operates primarily within the specialty pharmaceuticals and biotechnology industries, with a strategic emphasis on formulation science and drug-delivery technologies designed to improve the stability, usability, and administration of injectable therapies. Xeris generates revenue through commercialized products, licensing arrangements, and collaborations tied to its proprietary formulation platforms.

The company’s primary commercial products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous Cushing’s syndrome. A central differentiator is Xeris’ proprietary non-aqueous formulation technologies, including XeriSol and XeriJect, which are intended to enable room-temperature stable, ready-to-use injectable therapeutics. Founded in 2005 and headquartered in Chicago, Illinois, Xeris evolved from a drug-delivery platform company into a commercial-stage biopharmaceutical business through internal product development, regulatory approvals, and acquisitions, including the acquisition of Strongbridge Biopharma plc in 2021.

Business Operations

Xeris conducts operations primarily through its commercial and development-stage pharmaceutical businesses. Revenue is derived from product sales, particularly from Gvoke, Recorlev, and Keveyis, as well as from royalty and collaboration agreements associated with its formulation technologies. The company’s activities include drug development, regulatory affairs, commercialization, medical affairs, and lifecycle management of specialty therapeutics. Its portfolio is concentrated in rare disease and endocrinology markets, where treatment complexity and unmet clinical need can support specialty pricing and physician-focused commercialization models.

The company operates primarily in the United States, though certain products and intellectual property arrangements extend internationally through partnerships and licensing relationships. Xeris controls proprietary injectable drug formulation technologies designed to improve drug stability and eliminate refrigeration or reconstitution requirements in some therapies. Key operational assets include intellectual property related to XeriSol and XeriJect, manufacturing and supply-chain arrangements with third-party contract manufacturers, and commercial infrastructure targeting endocrinologists, neurologists, and specialty-care physicians. The acquisition of Strongbridge Biopharma plc expanded Xeris’ rare disease portfolio and added the commercial assets Keveyis and Recorlev.

Strategic Position & Investments

Xeris’ strategic direction has centered on expanding its commercial rare disease and endocrinology portfolio while leveraging its proprietary formulation technologies to support internal development programs and external collaborations. The company has emphasized growth through commercialization of approved products, lifecycle management initiatives, and selective business development opportunities. Public filings and investor communications indicate continued focus on driving adoption of Gvoke, increasing market penetration for Recorlev, and supporting long-term growth in rare disease therapeutics.

The acquisition of Strongbridge Biopharma plc represented a major strategic investment that materially expanded Xeris’ commercial scale and diversified its revenue base. Xeris has also pursued partnerships involving its formulation technologies in areas such as peptide and biologic drug delivery. The company has explored opportunities involving ready-to-use formulations for therapies requiring improved stability and easier administration. Its technology platforms position the company within emerging areas of specialty injectable therapeutics, particularly where reformulation can improve patient convenience, emergency administration, or storage logistics.

Geographic Footprint

Xeris is headquartered in Chicago, Illinois, and its primary commercial operations are concentrated in the United States. The company markets its approved products largely to U.S. healthcare providers, specialty pharmacies, hospitals, and patients with endocrine and rare neurological conditions. Its operational footprint includes commercial, medical, and regulatory functions supporting nationwide product distribution and physician engagement.

Although Xeris does not maintain the same international scale as large multinational pharmaceutical companies, it has international exposure through intellectual property holdings, licensing relationships, and inherited operations connected to the acquisition of Strongbridge Biopharma plc, which previously maintained activities in Ireland and other international jurisdictions. The company’s strategic influence outside the U.S. is primarily linked to partnerships, patent protections, and potential future commercialization opportunities in global specialty pharmaceutical markets.

Leadership & Governance

Xeris was founded by scientists and entrepreneurs focused on developing non-aqueous injectable formulations capable of improving drug stability and usability. The company’s leadership strategy has emphasized disciplined commercialization, expansion of rare disease assets, and continued investment in proprietary formulation technologies. Public corporate communications and SEC disclosures consistently highlight operational execution, portfolio diversification, and long-term value creation through specialty therapeutics and technology-enabled drug delivery.

Key executives include:

• John Shannon – Chief Executive Officer
• Steven Pieper – Chief Financial Officer
• Kristen Oglesby – Chief Operating Officer
• Kenneth Johnson – Senior Vice President, Global Commercial
• Jeffrey Sherman – Chief Medical Officer
• Richard D. King – Chairman of the Board

Company governance and operational disclosures are primarily detailed in SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, earnings materials, and investor presentations. Information regarding executive leadership, product portfolio, and strategic initiatives has been cross-verified through public filings and major financial and healthcare industry reporting sources.